Skip to main content
 

Investors & Media

Corporate Profile
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
November 10, 2016
WAVE Life Sciences Appoints Christian Henry to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the appointment of Christian Henry, Executive Vice President & Chief Commercial Officer of Illumina, Inc., to its Board of Directors and as the Chair of its Audit Committee. “The addition of Christian Henry to our Board complements... 
November 9, 2016
WAVE Life Sciences Reports Third Quarter 2016 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced financial results for the third quarter ended September 30, 2016. “WAVE continued its strong progress this quarter and we are on track to achieve our 2016 corporate goals, including the filing of two INDs in Huntington’s disease,... 
November 7, 2016
WAVE Life Sciences to Present at the Jefferies 2016 London Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016, at 8:40 A.M. GMT in London, United Kingdom. A live webcast will a... 

view all

Upcoming Events
There are currently no events scheduled.

view all